Our Resident Network
Meet Our Residents
LabCentral has generated significant interest from entrepreneurs and startups working on groundbreaking science who are eager to join LabCentral, a first-of-its-kind, fully resourced and equipped life-sciences laboratory space. Participants are chosen through a competitive process, where only the highest-potential applicants are selected in keeping with our mission.
AIRNA brings together leading academic scientists that pioneered a new field of precisely targeting RNA. The company's medicines will be antisense oligonucleotides which are specifically delivered to target tissues and make precise modifications to alter the RNA or associated protein function, interaction, or form. The company has licensed a strong patent portfolio to be a leader in this emerging field.
Kernal Bio is a biotech company developing mRNA 2.0 immunotherapies. Kernal mines translatome data to discover cell-specific sequence features and design mRNAs that are selectively translated in cancer cells. These mRNAs are formulated with proprietary, best-in-class LNPs validated in non-human primates. Our development candidates have a remarkably wide therapeutic index and can be systemically delivered with extrahepatic LNPs. Lead program shows high efficacy and safety in solid tumors resistant to other immuno-oncology agents. With roots at MIT, Harvard, Merck and BMS, Kernal’s management team has deep expertise in mRNA therapeutics with three FDA approvals and 120+ patents. Based in Cambridge, MA, the company is backed by Hummingbird, Amgen, HBM, Civilization Ventures, NASA, and Boeing.